Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
A recent study in Science Immunology describes a new approach to selectively eliminate pathogenic CD4+ T cells in inflammatory bowel disease by activating them in the presence of metabolic checkpoint inhibition.
